337 related articles for article (PubMed ID: 27733318)
1. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
[TBL] [Abstract][Full Text] [Related]
2. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
3. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
4. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
5. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
10. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
12. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
13. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.
Golfieri R; Giampalma E; Renzulli M; Cioni R; Bargellini I; Bartolozzi C; Breatta AD; Gandini G; Nani R; Gasparini D; Cucchetti A; Bolondi L; Trevisani F;
Br J Cancer; 2014 Jul; 111(2):255-64. PubMed ID: 24937669
[TBL] [Abstract][Full Text] [Related]
15. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Song MJ; Chun HJ; Song DS; Kim HY; Yoo SH; Park CH; Bae SH; Choi JY; Chang UI; Yang JM; Lee HG; Yoon SK
J Hepatol; 2012 Dec; 57(6):1244-50. PubMed ID: 22824821
[TBL] [Abstract][Full Text] [Related]
16. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]